NCT04711135View on ClinicalTrials.gov

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

March 12, 2024

Study Completion Date

May 7, 2034

Conditions
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Interventions
DRUG

Lutetium [177Lu] oxodotreotide/dotatate

Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

Trial Locations (7)

19104

Children's Hospital of Philadelphia, Philadelphia

40536

University of Kentucky, Lexington

45229-3039

Cincinnati Children's Hospital, Cincinnati

Unknown

Centre Léon Berard, Lyon

Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice

Hospital Universitari Vall d'Hebron, Barcelona

University College Hospital of London, London

Sponsors
All Listed Sponsors
lead

Advanced Accelerator Applications

INDUSTRY